Riskpilot← Back to searchSign inGet full accessGenedoc Pharmaceuticals AB
ABActiveOrg 5568613813Hammartorpsvägen 5 EResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20110 employees
Revenue 2025
SEK 1K
0% vs 2024
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2025
SEK 0
0 employees
| Revenue | SEK 1K | +0% |
| EBITDA | — | — |
| Net profit | SEK 0 | — |
| Total assets | SEK 0 | — |
| Equity | SEK 0 | — |
| Employees | 0 | — |
Legal name
Genedoc Pharmaceuticals AB
Org number
5568613813
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16 augusti 2011
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för företagets verksamhet är att genom forskning utveckla nya läkemedel. Företaget kommer medverka under de initiala stegen i att ta fram nya läkemedel för behandling av auto-immuna och auto-inflammatoriska sjukdomar, som exempelvis diabetes (typ1,2), ledgångsreumatism och multipel skleros. Samarbeten kommer att ske med forskargrupper som har anknytning till universitet och läkemedelsbolag.
Address
Hammartorpsvägen 5 E
Email
kjellen.peter@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 | 1 | 1 | 1 | 1 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | — | — | — | — |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 0 | 0 | 0 | 0 |
| Net financials | — | — | — | — | — |
| Profit before tax | 0 | 0 | 0 | 0 | 0 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | 0 | 0 | 0 | 0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 0 | 0 |
| Equity | 0 | 0 | 0 | 0 | 0 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 |
| Total debt | — | — | — | — | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20212025
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20212025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20212025
Asset turnover
1000.00×
This company
1.12×
Market median
+89186% vs market
20212025
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LP Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Genedoc Pharmaceuticals AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Peter Kjellén | Chief Executive Officer | 0 companies |
| Eric Harald Kjellén | Deputy Board Member | 0 companies |